Zacks Equity Research reviews biotech stocks poised for growth amid economic challenges
The biotech scene had a rough ride last year, and it seems like 2025 might not be much smoother. But hey, there’s always a need for new medical treatments, right? That’s what keeps the interest alive, even when things get bumpy.
Mergers and acquisitions are expected to pick up speed this year, especially with some changes in the government and a push for less regulation. Big pharma companies are always on the lookout to expand their portfolios, and smaller biotech firms with promising drugs could be the next big thing.
Incyte and BioMarin are already making waves with their strong drug pipelines. BioMarin’s drug for dwarfism is in high demand, and Incyte’s got a solid lineup too. Exelixis is doing well with its cancer treatment, and Halozyme is raking in cash from its partnerships.
Blueprint Medicines is also on the rise, especially with its drug for certain tumors. All in all, these companies are set to stand out in a tricky market. It’s definitely worth keeping an eye on them as they navigate through the ups and downs of the biotech world.
